List of Excipients in Branded Drug LUMIFY REDNESS RELIEVER EYE DROPS

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch & Lomb Incorporated	LUMIFY REDNESS RELIEVER EYE DROPS	brimonidine tartrate	24208-537	BENZALKONIUM CHLORIDE
Bausch & Lomb Incorporated	LUMIFY REDNESS RELIEVER EYE DROPS	brimonidine tartrate	24208-537	BORIC ACID
Bausch & Lomb Incorporated	LUMIFY REDNESS RELIEVER EYE DROPS	brimonidine tartrate	24208-537	CALCIUM CHLORIDE
Bausch & Lomb Incorporated	LUMIFY REDNESS RELIEVER EYE DROPS	brimonidine tartrate	24208-537	GLYCERIN

Lumify Redness Reliever Eye Drops: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: October 2, 2026

LUMIFY Redness Reliever Eye Drops is an OTC ophthalmic solution containing brimonidine tartrate 0.025%. Bausch + Lomb markets it for temporary relief of ocular redness. Its commercial differentiation comes from low-dose alpha-2 adrenergic activity, a relatively low ocular adverse-event profile, and a formulation that avoids the rebound-redness positioning associated with some older vasoconstrictors.[1][2]

The principal excipient opportunity is not basic efficacy. It is product-line expansion around preservative-free delivery, contact-lens compatibility, multidose packaging, longer shelf life, improved comfort, and differentiated dosing. The main commercial risk is substitution by low-cost redness-relief products and potential generic or private-label development if regulatory and intellectual-property barriers are limited.

What is the formulation of LUMIFY Redness Reliever Eye Drops?

LUMIFY contains brimonidine tartrate 0.025% in a preserved aqueous ophthalmic solution.

Component	Role in formulation
Brimonidine tartrate 0.025%	Active alpha-2 adrenergic agonist; reduces conjunctival vessel diameter
Boric acid	Buffering and tonicity contribution
Sodium borate decahydrate	Buffer system and pH control
Sodium chloride	Tonicity adjustment
Hypromellose	Viscosity enhancement, lubrication and residence-time support
Benzalkonium chloride	Preservative
Purified water	Vehicle

The FDA-approved product is supplied as an ophthalmic solution in a multidose container. The label instructs users to apply one drop in the affected eye or eyes every six to eight hours, with no more than four applications per day.[1]

The formulation uses a conventional aqueous ophthalmic platform, but its commercial value comes from the interaction between low brimonidine concentration, controlled pH, buffer capacity, viscosity, preservative protection and the dispensing system.

How does the Lumify excipient system support product performance?

The formulation has four practical objectives: maintain brimonidine stability, minimize ocular discomfort, control microbial risk, and deliver a reproducible drop.

pH and buffer system

The boric acid and sodium borate system controls pH during storage and use. Ophthalmic pH design requires a balance between active-ingredient stability, preservative performance, comfort and solubility. Excessive buffering can reduce tolerability when the product is repeatedly applied, while weak buffering can allow pH drift after container opening.

A follow-on formulation could seek a lower-buffer-capacity system, provided it maintains chemical stability and preservative effectiveness. Potential alternatives include phosphate, citrate or borate systems, although each creates different risks involving precipitation, irritation, interaction with packaging and regulatory comparability.

Tonicity control

Sodium chloride helps move the solution toward ocular tolerability. Hypotonic or hypertonic products can cause transient stinging, reflex tearing or blurred vision. Tonicity cannot be optimized separately from the active concentration, buffer concentration and polymer content.

Hypromellose

Hypromellose increases viscosity and can improve ocular surface residence time. It also may reduce the sensation of a rapidly draining aqueous drop. Higher viscosity, however, can increase blur, alter drop size and make the product less attractive for users seeking cosmetic convenience.

A commercial reformulation opportunity is a lower-viscosity lubricating system that preserves comfort without creating noticeable visual disturbance. Suitable polymers could include low-substitution hypromellose, hydroxypropyl guar, povidone or selected cellulose derivatives. Each would require evaluation for clarity, drop formation, filterability, preservative compatibility and container interaction.

Benzalkonium chloride

Benzalkonium chloride, or BAK, is an established ophthalmic preservative but has a recognized association with ocular-surface irritation and epithelial effects, particularly with frequent or chronic exposure.[3] LUMIFY is labeled for intermittent use, which reduces the relevance of cumulative preservative exposure compared with chronic glaucoma therapy. The presence of BAK nonetheless creates the clearest excipient-based product opportunity.

A preservative-free LUMIFY product could command a premium among frequent users, contact-lens wearers and consumers with dry-eye symptoms. The principal technical challenge is maintaining multidose microbial protection without BAK. Options include:

• Preservative-free unit-dose vials.
• One-way valve multidose containers.
• Sterile airless pump systems.
• Blow-fill-seal ampoules.
• Alternative preservative systems, subject to ophthalmic tolerability and FDA acceptance.

What formulations are protected or differentiated by the Lumify platform?

The commercial formulation can be segmented into four potential product architectures.

Product architecture	Commercial benefit	Main technical barrier
Current preserved multidose solution	Low cost and convenient use	BAK exposure and limited differentiation
Preservative-free unit dose	Premium positioning and ocular-surface appeal	Higher packaging and distribution cost
Preservative-free multidose	Convenience plus premium positioning	Container-closure microbial protection
Lubricating redness-relief formulation	Broader dry-eye and cosmetic appeal	Potential blur, altered pharmacokinetics and combination-product complexity

A contact-lens-compatible product is another opportunity. The current labeling should control any contact-lens positioning. A new product would require assessment of lens adsorption, preservative uptake, lens material compatibility and whether users remove lenses before instillation.

A formulation containing brimonidine with a lubricant could expand the target population, but it would require careful clinical and regulatory positioning. A lubricant does not automatically convert a redness-relief product into a dry-eye treatment, and claims would need to remain within the approved or permitted regulatory framework.

What is the FDA regulatory status of LUMIFY?

LUMIFY was approved by FDA as an OTC ophthalmic product under NDA 210817 in December 2017.[1][4] The active ingredient, brimonidine tartrate, was previously used in prescription ophthalmic products at materially higher concentrations, including products for glaucoma and ocular hypertension.

The lower 0.025% strength and consumer labeling distinguish LUMIFY from prescription brimonidine products. The product is not simply a monograph-era redness reliever. Its FDA status is tied to an approved NDA and its specific labeling, formulation and manufacturing controls.

Key regulatory considerations for a new entrant include:

1. Whether the proposed product can rely on an abbreviated pathway or requires a new NDA.
2. Whether the formulation is sufficiently comparable to the reference product.
3. Whether the applicant changes the preservative, container, viscosity, dosing or labeling.
4. Whether the proposed product is eligible for OTC use based on consumer comprehension and safe self-selection.
5. Whether the application includes adequate stability, sterility, preservative-effectiveness and container-closure data.

A substantial formulation change, such as preservative removal or a new delivery device, may create regulatory value but also increase development cost and approval risk.

What is the Orange Book and patent status of LUMIFY?

FDA approval and patent protection are separate questions. The reference product’s regulatory exclusivity, any listed patents, and the timing of an abbreviated application should be assessed from current FDA Orange Book and patent records.

For LUMIFY, the commercially important rights are likely to fall into several categories:

Rights category	Strategic relevance
Brimonidine concentration and use	May protect the low-dose redness-relief indication
Ophthalmic formulation	May cover excipient ranges, pH, viscosity, stability or preservative systems
Container and dispensing system	May protect multidose delivery or contamination control
Labeling and method of use	May affect OTC claim differentiation
Manufacturing process	May create a barrier where formulation patents are narrow

A competitor could pursue an authorized generic, a Paragraph IV challenge, a section 505(b)(2) application, or a distinct OTC ophthalmic product depending on the proposed formulation and regulatory pathway. A Paragraph IV strategy would be relevant only if the reference product has enforceable Orange Book-listed patents. A product with a materially different formulation may instead require a 505(b)(2) strategy or a full NDA route.

A live patent assessment should not rely on marketing materials or expired prosecution summaries. It must compare current Orange Book listings, patent-family status, terminal disclaimers, PTA or PTE adjustments, ownership changes and litigation records.

When could generic or competing entry occur?

The most credible entry scenarios are differentiated rather than purely identical copies.

Low-cost brimonidine solution

This is the highest price-pressure scenario. A competitor could seek a formulation close to the reference product and compete through retail pharmacy, e-commerce and private-label channels. The main barriers would be FDA approval, sterile manufacturing capacity, reference-product patents and market access.

Preservative-free premium product

This scenario may avoid direct price competition. A preservative-free product could target consumers with repeated use, dry-eye symptoms or concerns about BAK. Its value would depend on packaging cost, dosing convenience and clinical evidence supporting comfort.

Combination redness-relief and lubrication product

This product could capture users who want cosmetic redness reduction without sacrificing ocular comfort. It would require disciplined labeling and clinical support to prevent the product from being positioned as a treatment for conditions outside its approved scope.

Private-label retailer product

Retailers could seek a lower-priced product under store brands. The opportunity is strongest if the active ingredient is available through an approved pathway and the entrant can obtain sterile filling and national distribution. Retailer economics would favor a simple preserved multidose package rather than a premium device.

How strong is the Lumify patent estate?

Patent strength depends less on the existence of a single composition patent than on the breadth and enforceability of the combined estate.

A strong estate would include claims covering:

• Brimonidine at or near 0.025%.
• Treatment of ocular redness in a consumer population.
• Specific pH, buffer, viscosity and preservative ranges.
• Stability under accelerated and long-term conditions.
• Multidose dispensing and microbial protection.
• Labeling that directs intermittent use without rebound-redness claims.

A weaker estate would rely mainly on narrow excipient ranges or a formulation that competitors can design around. Formulation patents are most valuable when they connect a defined composition to measurable performance, such as improved stability, reduced irritation, controlled drop size or reduced rebound redness.

The principal non-patent barriers are sterile manufacturing validation, preservative-effectiveness testing, container-closure qualification, supply of pharmaceutical-grade brimonidine and retail-channel access.

Which companies could challenge LUMIFY commercially?

The competitive field includes:

Competitor group	Likely strategy
Generic ophthalmic manufacturers	Lower-price brimonidine or redness-relief products
OTC eye-care companies	Retail distribution and brand substitution
Private-label retailers	Store-brand pricing and shelf placement
Specialty ophthalmic companies	Preservative-free or comfort-focused reformulation
Device and packaging suppliers	Enabling multidose preservative-free delivery
International manufacturers	Region-specific OTC or pharmacy products

Bausch + Lomb has advantages in ophthalmic manufacturing, retail distribution, physician familiarity and brand recognition. A challenger would need either a lower cost structure or a clearly differentiated formulation.

What licensing and partnering opportunities exist?

The most attractive licensing targets are formulation and delivery technologies rather than the active ingredient alone.

Potential deal structures include:

1. A preservative-free multidose container license for use with brimonidine.
2. A regional commercialization agreement for Lumify or a follow-on product.
3. A co-development agreement for redness relief combined with ocular lubrication.
4. A private-label supply agreement using a contract sterile ophthalmic manufacturer.
5. A patent license covering stability-enhancing excipients or contamination-control packaging.

The value of a license would depend on freedom to operate, FDA compatibility, manufacturing scale and whether the technology supports a new claim or only reduces production cost.

What is the revenue exposure and commercial outlook?

LUMIFY operates in a high-volume OTC category where brand, shelf placement and repeat purchase matter. Revenue exposure is tied to:

• U.S. retail and e-commerce sales.
• Premium pricing relative to phenylephrine and naphazoline products.
• Repeat use by cosmetic and occasional users.
• International expansion.
• Product extensions such as larger bottles, preservative-free formats and travel packaging.

The largest revenue risk is erosion from cheaper products with similar consumer-perceived benefits. The largest upside is premium segmentation. A preservative-free product could expand gross margin per unit but may reduce unit volume because of higher packaging and manufacturing costs.

Key Takeaways

• LUMIFY contains brimonidine tartrate 0.025% in a preserved aqueous ophthalmic solution.
• The principal excipients are boric acid, sodium borate, sodium chloride, hypromellose, benzalkonium chloride and purified water.
• BAK removal is the clearest formulation opportunity.
• Preservative-free multidose delivery offers the strongest premium-product concept but requires robust container and microbial-control development.
• Low-cost generic entry would create the greatest price pressure.
• A challenger can differentiate through comfort, contact-lens compatibility, packaging, dosing convenience or lubrication.
• Patent value depends on the breadth of formulation, use, packaging and manufacturing claims, not merely on the active ingredient.
• LUMIFY is an FDA-approved OTC NDA product, not a simple unapproved monograph product.
• Manufacturing scale, sterile-filling capability and retail distribution are material barriers alongside patents.
• The most attractive licensing targets are preservative-free delivery systems and differentiated ophthalmic formulation technologies.

FAQs

Is benzalkonium chloride present in LUMIFY eye drops?

Yes. The FDA labeling identifies benzalkonium chloride as the preservative in the LUMIFY ophthalmic solution.[1]

Can a preservative-free version of brimonidine redness-relief drops be developed?

Yes, but the product would require a suitable unit-dose or multidose container system and supporting data for sterility, microbial control, stability and ocular tolerability.

Is LUMIFY the same as prescription brimonidine?

No. LUMIFY contains brimonidine tartrate 0.025% and is labeled for temporary relief of ocular redness. Prescription brimonidine products generally use higher concentrations and different indications.

Would a generic LUMIFY product automatically be therapeutically substitutable?

No. Substitutability depends on FDA approval, dosage form, formulation, labeling and applicable state pharmacy rules. A product with a different preservative or delivery system may require a different regulatory pathway.

What is the best commercial extension for LUMIFY?

A preservative-free, comfort-focused product in a convenient multidose package is the strongest extension concept. Its success would depend on packaging economics, consumer evidence and the ability to support premium pricing.

References

1. U.S. Food and Drug Administration. (2017). LUMIFY Redness Reliever ophthalmic solution, brimonidine tartrate 0.025%: Prescribing information and consumer labeling.
2. U.S. Food and Drug Administration. (2017). FDA approves first over-the-counter eye drop containing brimonidine tartrate for redness relief.
3. Baudouin, C., Labbé, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: LUMIFY, NDA 210817.